Issues related to the implementation of international tax and tax reform (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Duration: July 1, 2013
to
present
General Issues: Taxation/Internal Revenue Code , Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Budget/Appropriations
Spending: about $2,620,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jeff Forbes Staff Director, Senate Finance Committee
Chief of Staff, Senator Max Baucus
Deputy Asst, Special Asst, Deputy Director EOP
Derrick White Deputy Press Secretary, Senator Orrin Hatch
Rick Murphy Chief of Staff, Senator Kelly Ayotte, April 14 - Jan. 17
Francesca McCrary Legislative Assistant, Elijah Cummings (2016-2017); Professional Staff, House Oversight Reform Committee (2016-2016).
Cindy Brown Leg Assistant, Rep. Stupak, 1993-1994; Leg Director, Rep. Kind, 1999-2002; Chief of Staff, Rep. Kind, 2003-2009.
Barrett Thornhill Legislative Assistant, Sen. Mike Crapo (2003-2006); Legislative Assistant, Rep. Pat Toomey (2002-2003); Legislative Assistant, Rep. Charlie Norwood (2001-2002)
Libby Greer n/a
Jeff Strunk n/a
Jay Driscoll n/a
Ryan Welch n/a
Zach Williams n/a
Zachary Williams n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $80,000. The report was filed on April 14.
Original Filing: 301549309.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 16.
Original Filing: 301525791.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 18, 2023.
Original Filing: 301503515.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 16, 2023.
Original Filing: 301477089.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (P.L. 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260); Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 17, 2023.
Original Filing: 301452694.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (P.L. 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260); Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 15, 2023.
Original Filing: 301427811.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (P.L. 115-97); Issues related to Puerto Rico tax; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260); Issues related to H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 17, 2022.
Original Filing: 301405255.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax; Issues related to H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues related to H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 15, 2022.
Original Filing: 301381435.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement; Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars; Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 15, 2022.
Original Filing: 301357246.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $80,000. The report was filed on Jan. 16, 2022.
Original Filing: 301323376.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301384.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 16, 2021.
Original Filing: 301278060.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 17, 2021.
Original Filing: 301255045.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues regarding implementation of the CARES Act (Public Law No: 116-136).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301235885.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 18, 2020.
Original Filing: 301212667.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing; Issues related to H.R. 2693.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 18, 2020.
Original Filing: 301192812.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 18, 2020.
Original Filing: 301171705.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121421.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to prescription drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2019
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 19, 2019.
Original Filing: 301071937.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx Drug Pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2019
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 19, 2019.
Original Filing: 301051112.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx Drug Pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2019
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301034553.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx Drug Pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2018
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301013102.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 18, 2018.
Original Filing: 300989326.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 19, 2018.
Original Filing: 300969566.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 19, 2018.
Original Filing: 300949297.xml
Lobbying Issues
Issues related to the implementation of international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2017
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934806.xml
Lobbying Issues
Issues related to international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 16, 2017.
Original Filing: 300904746.xml
Lobbying Issues
Issues related to international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Rx pricing.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 19, 2017.
Original Filing: 300890036.xml
Lobbying Issues
Issues related to international tax and tax reform; Issues related to Puerto Rico tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300872847.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6 and part B demo; Issues regarding the ESRD bundle.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to international Tax and Tax Reform and issues related to Puerto Rico Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 19, 2017.
Original Filing: 300849763.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6 and part B demo; Issues regarding the ESRD bundle.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to international Tax and Tax Reform and issues related to Puerto Rico Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 19, 2016.
Original Filing: 300831819.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6 and part B demo; issues regarding the ESRD bundle.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to international Tax and Tax Reform and issues related to Puerto Rico Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 20, 2016.
Original Filing: 300816356.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6 and part B demo; issues regarding the ESRD bundle.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to international Tax and Tax Reform and issues related to Puerto Rico Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 20, 2016.
Original Filing: 300801389.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
Lobbying Issues
Issues related to international Tax and Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 20, 2016.
Original Filing: 300781250.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
Lobbying Issues
Issues related to international Tax and Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 20, 2015.
Original Filing: 300761606.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
Lobbying Issues
Issues related to international Tax and Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 20, 2015.
Original Filing: 300745264.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
Lobbying Issues
Issues related to international Tax and Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2015
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 16, 2015.
Original Filing: 300717607.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
Lobbying Issues
Issues related to international Tax and Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 20, 2015.
Original Filing: 300702586.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle. Issues related to 340B.
Lobbying Issues
Issues related to international Tax and Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 20, 2014.
Original Filing: 300683212.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle. Issues related to 340B.
Lobbying Issues
Issues related to international Tax and Tax Reform.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on July 19, 2014.
Original Filing: 300663488.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and issues dealing with ASP+6; issues regarding the ESRD bundle. Issues related to 340B.
1st Quarter, 2014
In Q1, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on April 21, 2014.
Original Filing: 300645855.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
4th Quarter, 2013
In Q4, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Jan. 16, 2014.
Original Filing: 300617065.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
3rd Quarter, 2013
In Q3, Forbes-Tate lobbied for Amgen USA, Inc. , earning $60,000. The report was filed on Oct. 16, 2013.
Original Filing: 300595094.xml
Lobbying Issues
Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitromety (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle.
3rd Quarter, 2013
Forbes-Tate filed a lobbying registration on July 29, 2013 to represent Amgen USA, Inc., effective July 1, 2013.
Original Filing: 300587998.xml
Issue(s) they said they’d lobby about: Issues related to Medicare Coverage and reimbursement issues pertaining to dialysis products and bone densitometry (DXA) and issues dealing with ASP+6; issues regarding the ESRD bundle. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...